Weekly funding opportunities

[med-Research]

Congressionally Directed Medical Research Programs
Lung Cancer Research Program<https://cdmrp.army.mil/funding/lcrp>
Career Development Award
Pre-application (required letter of intent): April 6. Full application: April 20.
Concept Award
Pre-application (required letter of intent): April 6. Full application: April 20.
Med-RA deadline to receive draft documents for April 20 full application due date: April 7.
Clinical Translational Research Partnership Award
Pre-application (required letter of intent): July 14. Full application: July 28.
Med-RA deadline to receive draft documents for July 14 full application due date: June 30 (due to July 4 holiday).
Investigator Initiated Translational Research Award
Pre-application (preproposal): May 5. Invited full application: July 28.
Med-RA deadline to receive draft documents for May 5 preproposal due date: April 22.

WITH Foundation: Comprehensive Healthcare for Adults with Developmental Disabilities<https://withfoundation.org/grant-guidelines/>
Established in 2002, the WITH Foundation works to provide comprehensive health care for adults with developmental disabilities that addresses their unique and fundamental needs. To that end, the foundation welcomes Letters of Intent from organizations in support of efforts to promote comprehensive health care for adults with developmental disabilities. Grants will be awarded in support of programs that improve delivery of health care to adult consumers with developmental disabilities and that include at least one of the following facets: improve health practitioner competency through education and/or training programs; address the currently inadequate reimbursement system; advance formal care coordination; enhance public awareness regarding the inadequacies of developmentally disabled care in order to advance systemic change; increase understanding of supported decision making in healthcare settings; conduct national efforts in digital health that support designers and developers and that include the perspectives/experiences of the IDD community within the design process in order to create better technology for all; conduct social policy research; and identify and overcome barriers to high-quality healthcare access. The foundation typically provides a year of support of between $30,000 and $50,000 but may cover as much as three years to support programming that warrants extended funding.
Letter of intent due April 9, 2021. Med-RA deadline to receive draft documents: March 29.

NIOSH Support for Conferences and Scientific Meetings (U13 Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/pa-files/PAR-21-193.html>
The purpose of the NIOSH Support for Conferences and Scientific Meetings (U13) is to support high quality scientific meetings, conferences, and workshops that are relevant to NIOSH’s scientific mission and that promote occupational safety and health, NIOSH program priorities, and public health. The conference program is integral to the overall mission of NIOSH. An application should address and advance important areas of research in the field of occupational safety and health of particular interest to NIOSH programs and the National Occupational Research Agenda. A conference or scientific meeting is defined as a gathering, symposium, seminar, workshop or any other organized and formal meeting where persons assemble in person or meet virtually to coordinate, exchange, and disseminate information or to explore or clarify a defined subject, problem, or area of knowledge.
Standard dates apply. Expires December 15, 2025. Med-RA deadline to receive draft documents for April 12 standard date: March 30.

The Midlife in the United States Study – Cognitive and Neurocognitive Precursors of AD/ADRD (U01 Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/pa-files/PAR-21-157.html>
The purpose of this Funding Opportunity Announcement (FOA) is to solicit Alzheimer’s disease and Alzheimer’s disease related dementias (AD/ADRD)-focused U01s that are ancillary to, but integrated with, the Midlife in the United States Study (MIDUS) U19 (see PAR-21-156<https://grants.nih.gov/grants/guide/pa-files/PAR-21-156.html>) to provide in-depth information to elucidate behavioral, social, psychological and biological pathways of risk and resilience to cognitive decline and AD/ADRD. In addition to capitalizing on already-collected data, new measures should be included to test hypotheses regarding development of AD/ADRD via cumulative stress exposures over 30 prior years of data collection. As well, the research should examine the protective influence of psychosocial resources, affective style, and lifestyle factors assessed over multiple prior waves of MIDUS. The new assessments on two national samples with many years of information on potential influences on AD/ADRD hold potential for yielding invaluable insights relevant for preventative interventions and treatments in future studies.
Due April 26, 2021 and November 18, 2021. Med-RA deadline to receive draft documents for April 26 due date: April 13.

Alex’s Lemonade Stand: Crazy 8 Initiative (Pediatric Cancers)<https://www.alexslemonade.org/sites/default/files/images/2020/crazy_8_rfa_2021_3.3.21.pdf>
The Crazy 8 Initiative Award will fund research into innovative and rigorous approaches that directly address the most intractable issues in pediatric cancer research today. This award is designed to coalesce cross-disciplinary cores of scientists working collaboratively in order to accelerate the pace of new cure discovery. Investigations may involve the exploration of a novel scientific hypothesis or the development of new model systems, tools or technologies that have the potential for significant impact on the field of childhood cancer. Collaboration and resource sharing are a priority for this research program. We expect successful applications to propose multidisciplinary teams with a very clear plan for collaboration that would empower the study of big ideas that would not be easily addressable otherwise. Childhood cancer research applicants are encouraged to bring new, necessary expertise into the field. For 2021, priority will be given to projects involving innovative studies of high-grade gliomas, nonmedulloblastoma embryonal brain tumors, non-Ewing Sarcoma fusion-positive sarcomas, fusion-negative sarcomas, big data and/or catalyzing clinical trials. Depending on the type of project and the size of the team, the requested budget should be in the range of $3-5 million USD over four years.
Letter of intent due April 26, 2021. Med-RA deadline to receive draft documents: April 13.

Simons Foundation Autism Research Initiative: Human Cognitive and Behavioral Science<https://www.sfari.org/grant/2021-human-cognitive-and-behavioral-science-request-for-applications/?tab=rfa>
Grants awarded through this RFA are intended to produce foundational knowledge about the neurobehavioral differences associated with ASD, which will directly inform the development or refinement of tools needed for translational efforts, such as biomarkers and outcome measures. Special emphasis is placed on objective, quantitative measures that may be used in conjunction with standardized clinical measures and genomic information to better triangulate phenotypic and neurobiological variability within and across individuals with ASD. The maximum budget is $750,000 or less, inclusive of 20 percent indirect costs, over a period of up to three years.
Due May 3, 2021. Med-RA deadline to receive draft documents: April 20.

Focused Ultrasound Foundation Clinical and Pre-clinical Awards<https://www.fusfoundation.org/for-researchers/about-our-awards>
Program Tracks include Brain<https://www.fusfoundation.org/for-researchers/about-our-awards/brain-program> and Cancer Immunotherapy<https://www.fusfoundation.org/for-researchers/about-our-awards/cancer-immunotherapy-program>.
Clinical Awards
The Foundation funds first-in-human and other innovative clinical trials involving the use of image-guided focused ultrasound to treat diseases. Funding for clinical trials is determined through a peer-review process, and the timing and dollar amounts are determined on a case-by-case basis. Priority is given to clinical indications with a clear patient need.
Pre-clinical Awards
Our Pre-Clinical Awards Program support investigator-initiated research projects in the form of one-year awards totaling approximately $100,000, paid out in three or more installments tied to progress reports throughout the term of the project. This program typically does not fund large capital purchases, overhead or institutional expenses, and the development of new focused ultrasound equipment. Exceptions to these guiding principles may be considered if the project addresses a gating factor in the near-term development of a reimbursable clinical application. Robust scientific design is prioritized over positive results (high failure risk is acceptable), and translational projects are preferred.
General Awards Program: Clinical Track and High-Risk Track<https://www.fusfoundation.org/for-researchers/about-our-awards/external-research-awards-program>
As a Pre-clinical Program Track, the General Awards Program provides funding for investigator-initiated research projects in the form of one-year awards totaling approximately $100,000, paid out in three or more installments tied to progress reports throughout the term of the project. The Pre-Clinical Track is geared primarily toward pre-clinical research and projects targeting one clinical indication or organ. It is meant to fund research that could lead the way to a new reimbursable clinical application for image-guided FUS within five to seven years. The High-Risk Track is intended for early-stage, high-risk, proof-of-concept research that, if successful, could have a profound impact on the field of focused ultrasound and that could change the way many conditions are treated.
One-page research abstracts accepted any time. Med-RA deadline to receive draft documents: 10 business days before submission to sponsor.

Cancer Prevention, Detection, Diagnosis, and Treatment Technologies for Global Health (U01 Clinical Trial Optional)<https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-21-030.html>
This Funding Opportunity Announcement (FOA) supports the development of cancer-relevant technologies suitable for use in low- and middle-income countries (LMICs). Specifically, the FOA solicits applications for projects to adapt, apply, and validate existing or emerging technologies into a new generation of user-friendly, low-cost technologies for preventing, detecting, diagnosing, and/or treating cancers in people living in LMICs. Applicants should have a working assay or device prototype (not necessarily already capable of cancer applications). The U01 project includes studies to both adapt this technology as well as demonstrate technical functionality and clinical performance for use of the device or assay in specific LMIC settings by meeting objective performance milestones followed by improvements and validations of the technologies in the LMIC settings. Projects proposed in response to this FOA will require multidisciplinary efforts to succeed; therefore, all applicant teams must include expertise in engineering/assay/treatment development, oncology, global healthcare delivery, and business development. Investigators responding to this FOA must consider affordability and cost-effectiveness as well as usability at the point-of-need as part of their design criteria.
Due June 2, 2021. Med-RA deadline to receive draft documents: May 19 (due to Memorial Day holiday).

New Directions in Hematology Research (SHINE-II) (R01 Clinical Trial Optional)<https://grants.nih.gov/grants/guide/pa-files/PAS-21-150.html>
This Funding Opportunity Announcement (FOA) seeks innovative grant applications in nonmalignant hematology research that will steer the field in new directions. Applications to this FOA should propose proof of principle research that is tightly focused into one specific aim, which can be accomplished within a 1-3 year project period, and is directed at validating novel concepts and approaches that promise to open new pathways for discovery.
Due June 5, 2021; October 5, 2021; February 5, 2022; June 5, 2022; October 5, 2022; February 5, 2023; June 5, 2023; October 5, 2023; February 5, 2024. Med-RA deadline to receive draft documents for June 5 due date: May 24.

NIMH Mental Disorders FOAs: R01s, R34, R33s, U01, R61 / R33s
The NIMH is soliciting clinical trial applications through a series of Funding Opportunity Announcements (FOAs) that cover the intervention development pipeline, from first in human, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials.
Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (Collaborative R01 Clinical Trial Required)<https://grants.nih.gov/grants/guide/pa-files/PAR-21-129.html>
This FOA seeks to support clinical trials to establish the effectiveness of interventions and to test hypotheses regarding moderators, mediators, and mechanisms of action of these interventions. This FOA supports clinical trials designed to test the therapeutic value of treatment and preventive interventions for which there is already evidence of efficacy, for use in community and practice settings. Applications might include research to evaluate the effectiveness or increase the clinical impact of pharmacologic, somatic, psychosocial (e.g., psychotherapeutic, behavioral), device-based, rehabilitative and combination interventions to prevent or treat mental illness. This FOA also supports clinical trials to test patient-, provider-, organizational-, or systems-level services interventions to improve access, continuity, quality, equity, and/or value of services. The intervention research covered under this announcement is explicitly focused on practice-relevant questions. This FOA supports trials that require participation of two or more collaborative sites for completion of the study. Accordingly, the collaborating studies share a specific protocol across the sites and are organized as such in order to increase sample size, accelerate recruitment, or increase sample diversity and representation. Each site has its own Program Director/Principal Investigator (PD/PI) and the program provides a mechanism for cross-site coordination, quality control, database management, statistical analysis, and reporting. This FOA is designed for applicants seeking funding for multi-site collaborative clinical trials to establish the effectiveness of interventions.
Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (R01 Clinical Trial Required)<https://grants.nih.gov/grants/guide/pa-files/PAR-21-130.html>
This FOA seeks to support clinical trials to establish the effectiveness of interventions and to test hypotheses regarding moderators, mediators, and mechanisms of action of these interventions. This FOA supports clinical trials designed to test the therapeutic value of treatment and preventive interventions for which there is already evidence of efficacy, for use in community and practice settings. Applications might include research to evaluate the effectiveness or increase the clinical impact of pharmacologic, somatic, psychosocial (e.g., psychotherapeutic, behavioral), device-based, rehabilitative and combination interventions to prevent or treat mental illness. This FOA also supports clinical trials to test patient-, provider-, organizational-, or systems-level services interventions to improve access, continuity, quality, equity, and/or value of services. The intervention research covered under this announcement is explicitly focused on practice-relevant questions. This FOA uses the R01 grant mechanism to support trials that are adequately powered and of sufficient scope to test effectiveness and examine mediators and moderators of response. This FOA is designed for applicants seeking funding for single-site clinical trials to establish the effectiveness of interventions.
Pilot Effectiveness Trials for Treatment, Preventive and Services Interventions (R34 Clinical Trial Required)<https://grants.nih.gov/grants/guide/pa-files/PAR-21-131.html>
The purpose of this FOA is to encourage pilot research consistent with NIMH’s priorities for: 1) effectiveness research on preventive and therapeutic interventions with previously demonstrated efficacy, for use with broader target populations or for use in community practice settings, and 2) research on the development and preliminary testing of innovative services interventions. Consistent with the NIMH experimental therapeutics approach, this FOA is intended to support pilot studies of intervention effectiveness or service delivery approaches that explicitly address whether the intervention engages the target(s)/mechanism(s) presumed to underlie the intervention effects (i.e., the mechanism(s) that accounts for changes in clinical/functional outcomes, changes in provider behavior, improved access or continuity of services, etc.).  In this pilot effectiveness phase of research, NIMH places highest priority on intervention and service delivery approaches that can be justified in terms of their potential to substantially impact practice and public health. This FOA supports pilot studies and provides resources for evaluating the feasibility, tolerability, acceptability and safety and preliminary effectiveness of approaches to improve mental health/functional outcomes, to modify risk factors, or to improve service delivery, and for obtaining the preliminary data needed as a prerequisite to a larger-scale effectiveness trial (e.g., comparative effectiveness study, pragmatic trial).
Confirmatory Efficacy Clinical Trials of Non-Pharmacological Interventions for Mental Disorders (R01 Clinical Trial Required)<https://grants.nih.gov/grants/guide/pa-files/PAR-21-132.html>
The purpose of this FOA is to support confirmatory efficacy testing of non-pharmacological therapeutic and preventive interventions for mental disorders in adults and children through an experimental therapeutics approach. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support “go/no-go” decisions about further development, effectiveness testing, or dissemination of the intervention. Interventions to be studied include, but are not limited to behavioral, cognitive, interpersonal, and device-based (both invasive/surgically implanted as well as noninvasive/transcranial) approaches, or a combination thereof. Interventions appropriate for efficacy testing must be based on a compelling scientific rationale, previous demonstration that the intervention engages and alters the hypothesized mechanism of action, a preliminary efficacy signal, and must address an unmet therapeutic need. Support will be provided for a trial of the intervention’s efficacy that includes measurement of the hypothesized mechanism of action and the relationship between change in the mechanism and change in functional or clinical effects. Ultimately, this FOA is intended to support a sufficiently-powered efficacy trial to determine the intervention’s potential for significant clinical benefit.
First in Human and Early Stage Clinical Trials of Novel Investigational Drugs or Devices for Psychiatric Disorders (U01 Clinical Trial Required)<https://grants.nih.gov/grants/guide/pa-files/PAR-21-133.html>
The purpose of this FOA is to encourage cooperative agreement applications to support early stage clinical trials of novel mechanism of action investigational drugs or novel neuromodulatory devices for the treatment of psychiatric disorders in areas of unmet medical need. The FOA will support milestone-driven early stage trials in pediatric and adult populations. First in human (FIH) and Phase Ib studies of novel agents must assess target engagement (brain exposure), pharmacological effects, safety, and tolerability to assess feasibility for Phase II/proof of concept (PoC) studies in psychiatric disorders. Phase II/PoC studies must evaluate the drug’s impact on clinically relevant physiological systems (functional measures) and clinical indicators of effect. The FOA also supports FIH and early feasibility studies (EFS) of novel devices to evaluate target engagement, safety, tolerability, and efficacy. The overall objective is to facilitate rapid collection of data to “de-risk” novel mechanism of action investigational drugs, novel drugs for use in pediatric populations with psychiatric disorders, and devices or combination treatments in order to attract private or other public funding (when appropriate) for further clinical development as FDA-approved treatments. A key aspect of this FOA is the formation of collaborative partnerships between the biomedical researchers and biotechnology or industry researchers to facilitate psychiatric drug or device development. This FOA is designed for applicants seeking funding for cooperative agreements supporting early stage clinical trials as outlined above.
Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R33 Clinical Trial Required)<https://grants.nih.gov/grants/guide/pa-files/PAR-21-134.html>
The purpose of this FOA is to encourage pilot research developing and testing innovative psychosocial intervention approaches in which the target and/or intervention strategy is novel. Consistent with NIMH’s experimental therapeutics approach, this FOA is intended to speed the translation of emergent research on mechanisms and processes underlying mental disorders into promising novel psychosocial preventative or therapeutic interventions. Targets may include, but are not limited to, potentially modifiable behavioral, cognitive, affective and/or interpersonal factors or processes, neural circuits or neural activity subserving specific behaviors or cognitive processes, and/or other neurobiological mechanisms. Novel psychosocial intervention strategies might include in-person or technology-assisted delivery, provided the target and/or the intervention strategy is novel. They may also be standalone interventions or augmentations of efficacious interventions for which there is an empirical rationale by which the augmentation (and corresponding target) is expected to substantially enhance outcomes. Support will be provided for up to 3 years for studies to replicate previous target engagement findings, and to relate change in the intervention target/mechanism to clinical benefit. Ultimately, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support “go/no-go” decisions about further development and/or testing of the intervention. This FOA is designed for applicants seeking to fund pilot stages of research.
Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33 Clinical Trial Required)<https://grants.nih.gov/grants/guide/pa-files/PAR-21-135.html>
The purpose of this FOA is to encourage pilot research developing and testing innovative psychosocial intervention approaches in which the target and/or intervention strategy is novel. Consistent with NIMH’s experimental therapeutics approach, this FOA is intended to speed the translation of emergent research on mechanisms and processes underlying mental disorders into promising novel psychosocial preventative or therapeutic interventions. Targets may include, but are not limited to, potentially modifiable behavioral, cognitive, affective and/or interpersonal factors or processes, neural circuits or neural activity subserving specific behaviors or cognitive processes, and/or other neurobiological mechanisms. Novel psychosocial interventions may be standalone interventions or augmentations to efficacious interventions for which there is an empirical rationale by which the augmentation (and corresponding target) is expected to substantially enhance outcomes. Support will be provided for up to two years (R61 phase) for preliminary milestone-driven testing of a novel intervention’s impact on a target process or mechanism associated mental disorder risk, causation, or maintenance (target engagement). Up to 3 years of additional support (R33 phase) will be provided for studies with findings that meet the “go/no-go” milestones embedded in the R61 phase. The R33 phase is intended to support the replication of target engagement and to test whether engaging the intervention target/mechanism mediates changes in clinical outcomes. Ultimately, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support “go/no-go” decisions about further development and/or testing of the intervention.
Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R33- Clinical Trial Required)<https://grants.nih.gov/grants/guide/pa-files/PAR-21-136.html>
The purpose of this FOA is to support the early stage testing of pharmacologic interventions with novel mechanisms of action or device-based interventions, for the treatment of symptoms or domains of altered functions in individuals with mental illness (e.g., schizophrenia, depression, autism, obsessive compulsive disorder, anxiety, bipolar disorder). Early intervention studies are also encouraged where symptoms of a disorder have been identified in subjects (a prodromal phase), prior to full diagnostic criteria being met. Ultimately, this FOA is intended to support early stage testing of pharmacologic or device-based interventions using a protocol design where the presumed mechanism of action of the intervention is adequately tested, to provide meaningful information where target modulation yields a well-controlled, dose-dependent neurophysiological/clinical/behavioral effect. Pediatric, adult and geriatric focused interventions are appropriate for this FOA. This R33 FOA supports single-phased clinical trial awards.
Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R61/R33 Clinical Trial Required)<https://grants.nih.gov/grants/guide/pa-files/PAR-21-137.html>
The purpose of this FOA is to support the early stage testing of pharmacologic interventions with novel mechanisms of action or device-based interventions for the treatment of symptoms or domains of altered functions in individuals with mental illness (e.g., schizophrenia, depression, autism, obsessive compulsive disorder, anxiety, bipolar disorder). Early intervention studies are also encouraged where symptoms of a disorder have been identified in subjects (a prodromal phase) prior to full diagnostic criteria being met. Ultimately, this FOA is intended to support early stage testing of pharmacologic or device-based interventions using a protocol design where the presumed mechanism of action of the intervention is adequately tested, to provide meaningful information where target modulation yields a well-controlled, dose-dependent neurophysiological/clinical/behavioral effect. The R61/R33 FOAs are intended to support biphasic high-risk applications.
Due June 15, 2021; October 15, 2021; February 15, 2022; June 15, 2022; October 14, 2022; February 15, 2022; June 15, 2023; October 17, 2023; February 15, 2024. Med-RA deadline to receive draft documents for June 15 due date: June 2.

Tropical Medicine Research Centers (U01 Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-21-004.html>
This funding opportunity announcement solicits research applications focused on the etiology, epidemiology, pathogenesis, clinical manifestations, diagnosis, prevention, treatment and control of select Neglected Tropical Diseases (NTDs) in endemic areas. The Tropical Medicine Research Centers (TMRCs) are intended to advance NIAID’s global research effort by targeting research endeavors to: develop novel diagnostic, prevention and therapeutic strategies adapted for the unique needs of low and middle-income countries (LMICs), as classified by the World Bank; create and sustain in-country research capacity; stimulate scientific collaboration and global partnerships; provide opportunities for junior and early-stage investigators to conduct research on NTDs; and facilitate sample sharing to support translational research to develop or evaluate new drugs, diagnostics, vaccines, therapeutics, and/or vector control strategies.
Due June 18, 2021. Med-RA deadline to receive draft documents: June 7.

Immune Cell Engineering For Targeted Therapy And Disease Monitoring in Type 1 Diabetes (R01 Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-21-005.html>
This initiative will support the engineering of immune cells to target the human pancreatic compartment to report on previously inaccessible information about diabetes initiation and progression, and/or to deliver environment-specific therapeutic responses to restore islet health and prevent the progression to T1D.
Due June 22, 2021. Med-RA deadline to receive draft documents: June 9.

Triadic Interactions in Clinical Encounters Involving People with Alzheimer’s Disease and Alzheimer’s Disease-Related Dementias (AD/ADRD), Clinicians, and Care Partners (R01 Clinical Trial Optional)<https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-22-020.html>
This Funding Opportunity Announcement (FOA) invites applications focused on triadic interactions and interpersonal processes between individuals with Alzheimer’s disease or Alzheimer’s disease-related dementias (AD/ADRD), clinicians, and care partners. NIA seeks to increase our understanding of the impact of such interactions on patient health and well-being outcomes. The goal of this initiative is to identify targets for the development of behavioral interventions to optimize interactions in clinical settings and help build and preserve strong and supportive caregiving relationships throughout all stages of AD/ADRD and across the continuum of care. To these ends, this FOA solicits basic research and Stage I behavioral intervention development clinical trials in two high-priority areas: (1) triadic communication and interpersonal relationships between patients, clinicians, and care partners; and (2) the clinical significance of dyadic processes in caregiving relationships between patients and care partners in the context of patient-caregiver-clinician encounters.
Due June 23, 2021. Med-RA deadline to receive draft documents: June 10.

Innovation for Tuberculosis Vaccine Discovery (ITVD) (R61/R33 Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-21-007.html>
To support the design of novel tuberculosis vaccine candidates that exploit innovative approaches and their advancement into preclinical animal model testing. This funding opportunity will use a milestone driven, biphasic award mechanism to fund high risk/exploratory research. Transition to the second phase depends on the successful completion of milestones.
Due June 30, 2021. Med-RA deadline to receive draft documents: June 17.

EMDR Foundation Research Grants<https://emdrresearchfoundation.org/research-grants/25000-emdr-research-grant-award/>
Grant awards of up to $25,000 are available for post-doctoral students, university faculty, or clinicians conducting research on Eye Movement Desensitization and Reprocessing (EMDR). Current research priorities include:
1st Priority – Advancing Evidence Based Practice: Increase the availability of quality EMDR research in areas where we already have a foot-hold in the literature but where more evidence is needed. Specifically, those areas are in the use of EMDR therapy to treat:

  *   Anxiety
  *   Depression
  *   Military PTSD
  *   Phantom Limb Pain
  *   To enhance recovery from the impact of cardiac events and the diagnosis and treatment of cancer
2nd Priority – Addressing the Global Burden of Trauma: Investigate the use of EMDR in natural or man-made disaster responses, by determining the effectiveness of the following protocols: early intervention protocols, the child or adult group protocols, or the use of EMDR standard protocols in disaster response.
3rd Priority – Building Clinical Evidence: There are a number of areas where EMDR therapy is being used, clinical observations are positive, and there are some research indicators of success. However, more research is needed to build a body of literature in these populations or diagnostic categories, including but not limited to:

  *   Addictions
  *   Eating disorders
  *   Dissociative disorders
  *   Additional medical/somatic conditions
  *   Suicide prevention and/or to address the impact of suicide
These priorities apply to research across the lifespan.
Due July 1, 2021. Med-RA deadline to receive draft documents: June 21.

Basic Research to Inform Vaccine and Therapeutic Development for Non-Polio Human Enteroviruses (NPEV) (R01 Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-21-006.html>
The purpose of this funding opportunity announcement is to solicit applications to expand basic research on non-polio enteroviruses (NPEV) that will inform the development of pan-enterovirus vaccines and broad-spectrum antivirals against enteroviruses A, B, C, and D.
Due July 13, 2021. Med-RA deadline to receive draft documents: June 29 (due to July 4 holiday).

Advancing technologies to improve delivery of pharmacological, gene editing, and other cargoes for HIV and SUD mechanistic or therapeutic research (R01- Clinical Trial Optional)<https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-22-010.html>
The purpose of this funding opportunity is to develop technologies to improve the delivery of pharmacological, gene editing, or other cargoes for HIV and SUD mechanistic research.
Due October 25, 2021 and October 25, 2022. Med-RA deadline to receive draft documents for October 2021 due date: October 12.

Forecasts

Research Grants for the Metabolic Dysregulation and Cancer Risk Program: a Transdisciplinary Approach to Obesity-Associated Research (U01 Clinical Trial Optional)<https://www.grants.gov/web/grants/view-opportunity.html?oppId=331885>
Estimated post date: May 1, 2021
Estimated application due date: October 1, 2021
The National Cancer Institute intends to solicit applications that will support transdisciplinary research projects on the dynamics and underlying mechanisms that link obesity, metabolic dysregulation, and increased cancer risk.

Understanding and Addressing the Impact of Structural Racism and Discrimination on Minority Health and Health Disparities (R01 - Clinical Trial Optional)<https://www.grants.gov/web/grants/view-opportunity.html?oppId=331887>
Estimated post date: April 9, 2021
Estimated application due date: August 20, 2021
The National Institute on Minority Health and Health Disparities, with other NIH Institutes, Centers, and Offices, intends to promote a new initiative soliciting applications on (1) observational research to understand the role of structural racism and discrimination (SRD) in causing and sustaining health disparities, and (2) intervention research that addresses SRD in order to improve minority health or reduce health disparities.

Program on the Origins of Gastroesophageal Cancers (R01 Clinical Trial Optional)<https://www.grants.gov/web/grants/view-opportunity.html?oppId=331891>
Estimated post date: May 1, 2021
Estimated application due date: September 1, 2021
This new program will build on recent molecular classifications of gastroesophageal cancers, significant understanding of their cancer genomics, and advances in stem cell research to examine and define how these related cancers initially evolve at the cellular level. The program will also examine the complex mechanisms and effectors that direct the proliferation and expansion of tumor initiating cells and their progeny to initiate these cancers. The focus of the FOA will be on gastric and gastroesophageal junction adenocarcinomas. The program is envisioned to provide unprecedented opportunities to outline the earliest cellular changes in transformation that precede any histological manifestation or neoplasia.

To search for additional funding opportunities, please visit CoM’s unofficial funding opportunities blog<https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV6980C-DCl-AxzFLHMVYQ&e=>.

-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://lists.fsu.edu/pipermail/com_funding_opportunities/attachments/20210312/af5aa37b/attachment.html>